Department of Medical Biotechnologies, University of Siena, Via delle Scotte, 6-53100 Siena, Italy.
Department of Pathology, Hospital Universitario Marques de Valdecilla, IFIMAV, Santander, Spain.
Infect Agent Cancer. 2014 Apr 14;9:12. doi: 10.1186/1750-9378-9-12. eCollection 2014.
Burkitt lymphoma is an aggressive B-cell lymphoma presenting in three clinical forms: endemic, sporadic and immunodeficiency-associated. More than 90% of endemic Burkitt lymphoma carry latent Epstein-Barr virus, whereas only 20% of sporadic Burkitt lymphoma are associated with Epstein-Barr infection. Although the Epstein-Barr virus is highly related with the endemic form, how and whether the virus participates in its pathogenesis remains to be fully elucidated. In particular, the virus may impair cellular gene expression by its own encoded microRNAs.
Using microRNA profiling we compared Epstein-Barr-positive and Epstein-Barr-negative Burkitt lymphoma cases for both cellular and viral microRNAs. The array results were validated by qRT-PCR, and potential targets of viral microRNAs were then searched by bioinformatic predictions, and classified in functional categories, according to the Gene Ontology. Our findings were validated by in vitro functional studies and by immunohistochemistry on a larger series of cases.
We showed that a few cellular microRNAs are differentially expressed between Epstein-Barr-positive and Epstein-Barr-negative Burkitt lymphoma cases, and identified a subset of viral microRNAs expressed in Epstein-Barr-positive Burkitt lymphomas. Of these, we characterized the effects of viral BART6-3p on regulation of cellular genes. In particular, we analyzed the IL-6 receptor genes (IL-6Rα and IL-6ST), PTEN and WT1 expression for their possible relevance to Burkitt lymphoma. By means of immunohistochemistry, we observed a down-regulation of the IL-6 receptor and PTEN specifically in Epstein-Barr-positive Burkitt lymphoma cases, which may result in the impairment of key cellular pathways and may contribute to malignant transformation. On the contrary, no differences were observed between Epstein-Barr-positive and Epstein-Barr-negative Burkitt lymphoma cases for WT1 expression.
Our preliminary results point at an active role for the Epstein-Barr virus in Burkitt lymphomagenesis and suggest new possible mechanisms used by the virus in determining dysregulation of the host cell physiology.
伯基特淋巴瘤是一种侵袭性 B 细胞淋巴瘤,有三种临床表现形式:地方性、散发性和免疫缺陷相关性。超过 90%的地方性伯基特淋巴瘤携带潜伏的 EBV,而只有 20%的散发性伯基特淋巴瘤与 EBV 感染有关。尽管 EBV 与地方性形式高度相关,但病毒如何以及是否参与其发病机制仍有待充分阐明。特别是,病毒可能通过自身编码的 microRNAs 损害细胞基因表达。
我们使用 microRNA 谱分析比较了 EBV 阳性和 EBV 阴性伯基特淋巴瘤病例的细胞和病毒 microRNAs。阵列结果通过 qRT-PCR 进行验证,然后通过生物信息学预测搜索潜在的病毒 microRNA 靶标,并根据基因本体论将其分类为功能类别。我们的发现通过体外功能研究和对更大系列病例的免疫组织化学验证得到了验证。
我们表明,一些细胞 microRNAs 在 EBV 阳性和 EBV 阴性伯基特淋巴瘤病例之间表达差异,并且鉴定了 EBV 阳性伯基特淋巴瘤中表达的一组病毒 microRNAs。其中,我们描述了病毒 BART6-3p 对细胞基因调节的影响。特别是,我们分析了 IL-6 受体基因(IL-6Rα 和 IL-6ST)、PTEN 和 WT1 的表达,以确定它们与伯基特淋巴瘤的可能相关性。通过免疫组织化学,我们观察到 EBV 阳性伯基特淋巴瘤病例中 IL-6 受体和 PTEN 的表达下调,这可能导致关键细胞途径受损,并可能有助于恶性转化。相反,在 EBV 阳性和 EBV 阴性伯基特淋巴瘤病例之间,WT1 的表达没有差异。
我们的初步结果表明 EBV 在伯基特淋巴瘤发生中的积极作用,并提出了病毒用于确定宿主细胞生理学失调的新可能机制。